Ultragenyx Pharmaceutical (RARE) Competitors $35.41 -1.94 (-5.19%) Closing price 04:00 PM EasternExtended Trading$35.42 +0.01 (+0.01%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. GMAB, RDY, VTRS, MRNA, QGEN, ASND, ROIV, RVMD, BBIO, and BPMCShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Genmab A/S Dr. Reddy's Laboratories Viatris Moderna Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines BridgeBio Pharma Blueprint Medicines Genmab A/S (NASDAQ:GMAB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends. Which has more risk and volatility, GMAB or RARE? Genmab A/S has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Does the MarketBeat Community prefer GMAB or RARE? Ultragenyx Pharmaceutical received 672 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.54% of users gave Ultragenyx Pharmaceutical an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote. CompanyUnderperformOutperformGenmab A/SOutperform Votes16763.02% Underperform Votes9836.98% Ultragenyx PharmaceuticalOutperform Votes83977.54% Underperform Votes24322.46% Is GMAB or RARE more profitable? Genmab A/S has a net margin of 36.30% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Genmab A/S's return on equity of 16.78% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S36.30% 16.78% 13.79% Ultragenyx Pharmaceutical -101.60%-193.80%-38.15% Do institutionals and insiders hold more shares of GMAB or RARE? 7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer GMAB or RARE? In the previous week, Genmab A/S had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 20 mentions for Genmab A/S and 16 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.12 beat Genmab A/S's score of 0.70 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend GMAB or RARE? Genmab A/S presently has a consensus target price of $39.17, suggesting a potential upside of 92.65%. Ultragenyx Pharmaceutical has a consensus target price of $90.93, suggesting a potential upside of 143.46%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has preferable valuation and earnings, GMAB or RARE? Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B4.18$1.14B$1.7611.55Ultragenyx Pharmaceutical$590.69M5.98-$569.18M-$5.88-6.35 SummaryGenmab A/S beats Ultragenyx Pharmaceutical on 10 of the 19 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.53B$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-5.899.1426.7920.05Price / Sales5.98255.59395.67116.44Price / CashN/A65.8538.2534.62Price / Book13.536.546.864.61Net Income-$569.18M$143.51M$3.22B$248.19M7 Day Performance7.57%5.60%6.80%2.97%1 Month Performance5.51%10.06%13.69%16.58%1 Year Performance-7.96%-0.86%18.25%8.16% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical3.9661 of 5 stars$35.41-5.2%$90.93+156.8%-10.1%$3.35B$590.69M-5.591,310Positive NewsGMABGenmab A/S3.4467 of 5 stars$19.91+2.8%$39.17+96.8%-31.5%$12.76B$21.64B11.441,660News CoverageHigh Trading VolumeRDYDr. Reddy's Laboratories2.3333 of 5 stars$13.93+3.9%$17.00+22.1%+5.3%$11.62B$311.31B22.1724,800Positive NewsGap UpVTRSViatris2.0946 of 5 stars$8.95+2.0%$10.50+17.4%-19.8%$10.61B$14.33B-12.0937,000Trending NewsGap UpMRNAModerna4.4677 of 5 stars$25.68+5.9%$53.95+110.1%-80.2%$9.93B$3.14B-2.773,900News CoverageGap UpQGENQiagen4.0353 of 5 stars$42.92+2.5%$48.42+12.8%-3.4%$9.54B$1.98B119.526,030Positive NewsASNDAscendis Pharma A/S3.521 of 5 stars$154.93+2.4%$216.07+39.5%+33.5%$9.45B$368.70M-21.82640ROIVRoivant Sciences1.9915 of 5 stars$10.98+3.1%$17.50+59.5%-2.9%$7.83B$122.59M-73.16860Positive NewsRVMDRevolution Medicines4.4108 of 5 stars$41.85+3.5%$67.17+60.5%+1.1%$7.79B$742,000.00-11.66250Positive NewsBBIOBridgeBio Pharma4.6002 of 5 stars$35.65+4.3%$57.09+60.1%+14.2%$6.77B$127.42M-12.51400Positive NewsInsider TradeBPMCBlueprint Medicines2.6687 of 5 stars$100.24+3.2%$126.56+26.3%-1.2%$6.47B$562.12M-92.81640Positive News Related Companies and Tools Related Companies Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Viatris Alternatives Moderna Alternatives Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.